Data from the CodeBreaK 300 study showed that treatment with Lumakras plus Vectibix led to superior progression-free survival (PFS) versus the investigated standard-of-care (SOC) in KRAS G12C-muta ...

Dublin, April 16, 2025 (GLOBE NEWSWIRE) -- The "KRAS Inhibitors Market, Drug Sales, Patent, Price & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering.

The green light comes on the strength of data from the phase 3 CodeBreaK 300 study, which showed that Lumakras plus Vectibix was the first targeted treatment combination to show superior ...

The FDA's conditional approval for Lumakras (sotorasib; formerly AMG-510) as a second-line treatment for KRAS G12c-mutated non-small cell lung cancer (NSCLC) has come more than two months ahead of ...

HAIKOU, August 24. /TASS/. An innovative American drug Lumakras (also known as Sotorasib) for lung cancer and other types of cancer may soon become available at Hainan Lecheng Medical Cluster ...